Sofosbuvir regimen outperformed other therapies in reducing liver complications in HCV patients
CHICAGO — Chronic hepatitis C virus-infected patients treated with a sofosbuvir-based regimen showed a reduced number of liver disease complications, compared with patients receiving other treatments, according to research presented at Digestive Disease Week 2014.
Sammy Saab, MD, MPH, AGAF, of UCLA Medical Center, and colleagues used a decision-analytic Markov model to compare health outcomes among chronic hepatitis C virus (HCV) patients with genotypes 1 to 4 who received a combination of sofosbuvir (SOF; Sovaldi, Gilead Sciences) and other therapies with HCV patients who did not. Outcome measures included complications resulting in mortality, liver transplantation, compensated cirrhosis, decompensated cirrhosis and hepatocellular carcinoma.
The researchers compared genotype (GT)-1 patients who received SOF plus pegylated-interferon and ribavirin (PegIFN/RBV) for 12 weeks vs. PegIFN/RBV, boceprevir plus PegIFN/RBV or telaprevir and PegIFN/RBV for 24 to 48 weeks. Comparisons for GT-2 patients were made between those assigned SOF with RBV for 12 weeks compared with PegIFN/RBV for 24 to 48 weeks. In GT-3 patients, evaluations included those assigned SOF plus RBV for 24 weeks vs. PegIFN/RBV for 24 to 48 weeks. GT-4 patients were assigned SOF and PegIFN/RBV and compared with PegIFN/RBV.
Patients who were treated with SOF displayed reductions of at least 30% in the incidence of liver disease complications compared with those did not receive SOF. In the GT-1 group, reductions were between 31% and 78%; reductions ranged up to 93% in the GT-2 group; and declines reached 87% among GT-3 patients. A 76% decrease in complications was observed among GT-4 patients.
“Sofosbuvir-based therapy is considered dominant in terms of efficacy and lower costs,” Saab said at the conference.
For more information:
Saab S. #474. Presented at: Digestive Disease Week 2014; May 3-6; Chicago.
Disclosure: The researchers report numerous relevant financial disclosures.